PAVmed Inc. (NASDAQ:PAVM) Short Interest Up 299.7% in June

Posted by Brian Himes on Jul 13th, 2026

PAVmed Inc. (NASDAQ:PAVM – Get Free Report) saw a large increase in short interest in June. As of June 30th, there was short interest totaling 33,650 shares, an increase of 299.7% from the June 15th total of 8,418 shares. Based on an average trading volume of 35,155 shares, the days-to-cover ratio is currently 1.0 days. Approximately 3.9% of the shares of the stock are short sold.

PAVmed Trading Down 1.8%

Shares of NASDAQ PAVM traded down $0.10 during trading on Monday, reaching $5.50. The company had a trading volume of 6,195 shares, compared to its average volume of 23,012. The company’s fifty day moving average price is $5.78 and its 200-day moving average price is $8.07. PAVmed has a 12 month low of $3.85 and a 12 month high of $28.44. The stock has a market cap of $5.50 million, a P/E ratio of -0.15 and a beta of 0.54. The company has a quick ratio of 2.02, a current ratio of 2.02 and a debt-to-equity ratio of 0.70.

PAVmed (NASDAQ:PAVM – Get Free Report) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($1.17) earnings per share for the quarter, missing the consensus estimate of ($0.69) by ($0.48). The company had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.07 million. PAVmed had a negative net margin of 21,914.12% and a negative return on equity of 146.19%. As a group, research analysts expect that PAVmed will post -2.74 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have issued reports on PAVM. Weiss Ratings reaffirmed a “sell (d)” rating on shares of PAVmed in a report on Tuesday, April 21st. Ascendiant Capital Markets cut their price target on PAVmed from $65.00 to $56.00 and set a “buy” rating on the stock in a research note on Monday, June 8th. Finally, Wall Street Zen upgraded PAVmed from a “sell” rating to a “hold” rating in a report on Saturday, April 4th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $56.00.

View Our Latest Stock Report on PAVM

Institutional Inflows and Outflows

A hedge fund recently raised its stake in PAVmed stock. Jane Street Group LLC grew its position in PAVmed Inc. (NASDAQ:PAVM – Free Report) by 392.9% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 52,676 shares of the company’s stock after purchasing an additional 41,990 shares during the quarter. Jane Street Group LLC owned approximately 0.31% of PAVmed worth $32,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 19.93% of the company’s stock.

PAVmed Company Profile

(Get Free Report)

PAVmed Inc is a clinical-stage medical technology company focused on acquiring, developing and commercializing innovative medical devices aimed primarily at gastrointestinal endoscopy and related therapeutic areas. Its portfolio includes FDA-cleared products such as EsoFLIP® Distensibility System for the treatment of esophageal strictures and MUSE™ (Medigus Ultrasonic Surgical Endostapler) for endoscopic fundoplication in gastroesophageal reflux disease (GERD). In addition to its gastrointestinal franchise, PAVmed is advancing early-stage programs targeting indications in oncology, urology and dermatology.

Founded in 2012, PAVmed has built its pipeline through internal research and development as well as strategic collaborations and acquisitions.